Contineum Therapeutics, Stock Forecast - Simple Exponential Smoothing
| CTNM Stock | 12.68 0.37 3.01% |
The Simple Exponential Smoothing forecasted value of Contineum Therapeutics, Class on the next trading day is expected to be 12.68 with a mean absolute deviation of 0.34 and the sum of the absolute errors of 20.27. Contineum Stock Forecast is based on your current time horizon. Although Contineum Therapeutics,'s naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Contineum Therapeutics,'s systematic risk associated with finding meaningful patterns of Contineum Therapeutics, fundamentals over time.
Contineum | Build AI portfolio with Contineum Stock |
Open Interest Against 2026-02-20 Contineum Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Contineum Therapeutics,'s spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Contineum Therapeutics,'s options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Contineum Therapeutics, stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Contineum Therapeutics,'s open interest, investors have to compare it to Contineum Therapeutics,'s spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Contineum Therapeutics, is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Contineum. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Contineum Therapeutics, Simple Exponential Smoothing Price Forecast For the 26th of December
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Contineum Therapeutics, Class on the next trading day is expected to be 12.68 with a mean absolute deviation of 0.34, mean absolute percentage error of 0.22, and the sum of the absolute errors of 20.27.Please note that although there have been many attempts to predict Contineum Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Contineum Therapeutics,'s next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Contineum Therapeutics, Stock Forecast Pattern
| Backtest Contineum Therapeutics, | Contineum Therapeutics, Price Prediction | Buy or Sell Advice |
Contineum Therapeutics, Forecasted Value
In the context of forecasting Contineum Therapeutics,'s Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Contineum Therapeutics,'s downside and upside margins for the forecasting period are 8.70 and 16.66, respectively. We have considered Contineum Therapeutics,'s daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Contineum Therapeutics, stock data series using in forecasting. Note that when a statistical model is used to represent Contineum Therapeutics, stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.738 |
| Bias | Arithmetic mean of the errors | -0.0278 |
| MAD | Mean absolute deviation | 0.3378 |
| MAPE | Mean absolute percentage error | 0.0295 |
| SAE | Sum of the absolute errors | 20.27 |
Predictive Modules for Contineum Therapeutics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Contineum Therapeutics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Other Forecasting Options for Contineum Therapeutics,
For every potential investor in Contineum, whether a beginner or expert, Contineum Therapeutics,'s price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Contineum Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Contineum. Basic forecasting techniques help filter out the noise by identifying Contineum Therapeutics,'s price trends.Contineum Therapeutics, Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Contineum Therapeutics, stock to make a market-neutral strategy. Peer analysis of Contineum Therapeutics, could also be used in its relative valuation, which is a method of valuing Contineum Therapeutics, by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Contineum Therapeutics, Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Contineum Therapeutics,'s price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Contineum Therapeutics,'s current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Contineum Therapeutics, Market Strength Events
Market strength indicators help investors to evaluate how Contineum Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Contineum Therapeutics, shares will generate the highest return on investment. By undertsting and applying Contineum Therapeutics, stock market strength indicators, traders can identify Contineum Therapeutics, Class entry and exit signals to maximize returns.
Contineum Therapeutics, Risk Indicators
The analysis of Contineum Therapeutics,'s basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Contineum Therapeutics,'s investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting contineum stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.1 | |||
| Semi Deviation | 3.74 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.35 | |||
| Downside Variance | 15.63 | |||
| Semi Variance | 13.99 | |||
| Expected Short fall | (3.59) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Historical Fundamental Analysis of Contineum Therapeutics, to cross-verify your projections. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.